HAYA Therapeutics secures $65 million in Series A funding led by Sofinnova Partners and Earlybird Venture Capital to advance its innovative heart failure therapy, HTX-001, and enhance its RNA-guided regulatory genome platform.

Information on the Target

HAYA Therapeutics SA is an innovative biotechnology firm specializing in the development of precision medicines that target regulatory RNAs sourced from the dark genome. This approach aims to reprogram pathogenic cell states associated with a variety of diseases, particularly focusing on cardiovascular and metabolic conditions, as well as cancer. The company has become a leader in this field, driven by its comprehensive research and development efforts, which utilize cutting-edge computational and machine learning methodologies to decode complex pathological processes.

Recently, HAYA Therapeutics announced the closure of a $65 million Series A funding round. The investment will primarily be utilized to advance the clinical development of HTX-001, its pioneering long non-coding RNA (lncRNA) therapeutic candidate designed for treating heart failure, specifically targeting non-obstructive hypertrophic cardiomyopathy (nHCM). In addition, the company is set to enhance its regulatory genome platform and expand its pipeline of therapies for multiple disease areas.

Industry Overview in Switzerland

Switzerland has established itself as a leading hub for biotechnology and life sciences, thanks to its favorable regulatory environment and significant investment in research and development. The country is home to numerous established pharmaceuti